Textbook of Clinical Trials in Oncology

A Statistical Perspective

By: Susan Halabi and Stefan Michiels

Write A Review

eText | 24 April 2019 | Edition Number 1

At a Glance

Format
ePUB

eText

$111.10

or 4 interest-free payments of $27.77 with

Instant online reading in your Booktopia eTextbook Library *

Read online on

Desktop

Tablet

Mobile

Not downloadable to your eReader or an app

Why choose an eTextbook?

Instant Access *

Purchase and read your book immediately

Read Aloud

Listen and follow along as Bookshelf reads to you

Study Tools

Built-in study tools like highlights and more

* eTextbooks are not downloadable to your eReader or an app and can be accessed via web browsers only. You must be connected to the internet and have no technical issues with your device or browser that could prevent the eTextbook from operating.

There is an increasing need for educational resources for statisticians and investigators. Reflecting this, the goal of this book is to provide readers with a sound foundation in the statistical design, conduct, and analysis of clinical trials. Furthermore, it is intended as a guide for statisticians and investigators with minimal clinical trial experience who are interested in pursuing a career in this area. The advancement in genetic and molecular technologies have revolutionized drug development. In recent years, clinical trials have become increasingly sophisticated as they incorporate genomic studies, and efficient designs (such as basket and umbrella trials) have permeated the field. This book offers the requisite background and expert guidance for the innovative statistical design and analysis of clinical trials in oncology.

Key Features:

Cutting-edge topics with appropriate technical background
Built around case studies which give the work a "hands-on" approach
Real examples of flaws in previously reported clinical trials and how to avoid them
Access to statistical code on the book's website
Chapters written by internationally recognized statisticians from academia and pharmaceutical companies
Carefully edited to ensure consistency in style, level, and approach
Topics covered include innovating phase I and II designs, trials in immune-oncology and rare diseases, among many others